Disrupting tumor onset and growth via selective cell tagging (SeCT) therapy

Kenward Vong, Tsuyoshi Tahara, Sayaka Urano, Igor Nasibullin, Kazuki Tsubokura, Yoichi Nakao, Almira Kurbangalieva, Hirotaka Onoe, Yasuyoshi Watanabe, Katsunori Tanaka

研究成果: Article査読

抄録

This study presents the early framework of selective cell tagging (SeCT) therapy, which is the concept of preferentially labeling specific cells in vivo with chemical moieties that can elicit a therapeutic response. Using glycosylated artificial metalloenzyme (GArM)-based protein labeling, this study reports two separate functional strategies. In one approach, early tumor onset can be suppressed by tagging cancer cells in living mice with an integrin-blocking cyclic-Arg-Gly-Asp (cRGD) moiety, thereby disrupting cell adhesion onto the extracellular matrix. In another approach, tumor growth in mice can be reduced by tagging with a cytotoxic doxorubicin moiety. Subsequent cell death occurs following internalization and drug release. Overall, experiments have shown that mouse populations receiving the mixture of SeCT labeling reagents exhibited a significant delay/reduction in tumor onset and growth compared with controls. Highlighting its adaptability, this work represents a foundational step for further development of SeCT therapy and its potential therapeutic applications.

本文言語English
論文番号eabg4038
ジャーナルScience Advances
7
17
DOI
出版ステータスPublished - 2021 4 21

ASJC Scopus subject areas

  • 一般

フィンガープリント

「Disrupting tumor onset and growth via selective cell tagging (SeCT) therapy」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル